Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

Top Cited Papers
Open Access
Abstract
No abstract available
Funding Information
  • Sanofi
  • Regeneron Pharmaceuticals
  • Sanofi
  • Regeneron Pharmaceuticals
  • Celgene
  • Novartis
  • Regeneron Pharmaceuticals
  • Sanofi Genzyme
  • AstraZeneca
  • Lilly
  • Incyte
  • Janssen
  • Novartis
  • Promius
  • Regeneron Pharmaceuticals
  • Pfizer
  • Valeant
  • AbbVie
  • Aquinox Pharma
  • Arcutis Antiobix
  • Asana
  • Astellas
  • Boehringer Ingelheim
  • Brickell Biotech
  • Dermavant
  • Dermira
  • Dignity Sciences
  • Lilly
  • Galderma
  • Glenmark
  • GlaxoSmithKline
  • Hoffman-La Roche
  • Kiniksa
  • Incyte
  • LEO Pharma
  • Neokera
  • Pfizer
  • Ralexar
  • Regeneron Pharmaceuticals
  • Sanofi Genzyme
  • Vitae
  • 3M
  • Aimmune
  • AstraZeneca
  • Circassia
  • Genentech
  • Galderma
  • Glenmark
  • LEO Pharma
  • Menlo Therapeutics
  • Novartis
  • Optinose
  • Pfizer
  • Regeneron Pharmaceuticals
  • Ralexar
  • Roche
  • Sanofi
  • Stallergenes
  • Teva
  • AbbVie
  • Amgen
  • BMS
  • Boehringer Ingelheim
  • Celgene
  • Celtaxsys
  • Cutanea
  • Dermira
  • Lilly
  • Galderma
  • Genentech
  • GlaxoSmithKline
  • Janssen
  • LEO Pharma
  • Merck
  • Novartis
  • Pfizer
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi
  • Sun Pharma
  • UCB
  • Valeant
  • GlaxoSmithKline
  • Kaken Pharmaceutical
  • Kyowa Hakko Kirin
  • Mitsubishi-Tanabe
  • Merck Sharp & Dohme
  • Taiho Pharmaceutical
  • Teikoku Seiyaku
  • Sanofi
  • Therakos
  • University of Pennsylvania
  • AbbVie
  • Lilly
  • Janssen
  • Novartis
  • Regeneron Pharmaceuticals
  • Sanofi
  • Pfizer

This publication has 39 references indexed in Scilit: